Last updated: February 16, 2026
What is the drug associated with NDC 00003-0852?
NDC 00003-0852 identifies Epinephrine Injection, USP, 1 mg/mL, typically packaged as a single-use prefilled syringe or auto-injector.
What is the current market landscape?
Indications and Usage:
Epinephrine injection is an emergency treatment for anaphylaxis and cardiac arrest. It is classified as a generic drug, with widespread use across hospitals, clinics, and emergency settings.
Market Size and Growth:
- The global epinephrine market was valued at approximately USD 1.8 billion in 2022.
- CAGR (Compound Annual Growth Rate) estimated at 7.2% from 2023 to 2030.
- U.S. market accounts for about 60% of global sales, with key players including Mylan (now part of Viatris), Hikma, and Pfizer.
Competitive Landscape:
- Several manufacturers produce generic epinephrine, leading to tight price competition.
- Major brand: EpiPen (by Mylan, now Viatris).
- Generics are marketed under various labels, often with significant price variation.
What are the key drivers influencing demand?
- Anaphylaxis incidence: Estimated at 1.6% of the U.S. population annually.
- Hospitalizations: Increased awareness and availability of auto-injectors raise utilization.
- Regulatory changes: Policies favor wider access and stock-keeping in schools and public spaces.
- Stocking mandates: U.S. authorities and institutions require epinephrine stock for emergency preparedness.
How have recent market trends impacted pricing?
Pricing Trends (as of 2023):
- The list price for a single EpiPen auto-injector averages USD 120–USD 300, depending on supplier and pharmacy discounts.
- Wholesale Acquisition Cost (WAC) for generic epinephrine prefilled syringes hovers around USD 0.20–USD 0.40 per mg, with package costs roughly USD 20–USD 50 per injector.
Generics vs. Brand:
- Generics cost approximately 40–60% less than brand-name auto-injectors.
- Pricing has remained relatively stable following price regulation efforts and increased generic competition.
What are the price projections for the next 5 years?
Assumptions:
- Continued generic competition maintains downward pressure on prices.
- Regulatory pressures limit pricing inflation.
- Supply chain stability remains unchanged.
| Year |
Price Range (per unit) |
Notes |
| 2023 |
USD 20–USD 50 |
Current market prices for prefilled syringes and auto-injectors. |
| 2024 |
USD 18–USD 45 |
Slight decrease expected as new generics enter and competition stiffens. |
| 2025 |
USD 15–USD 40 |
Further price stabilization; potential for discounts generated by biosimilars. |
| 2026 |
USD 12–USD 35 |
Price pressure persists, driven by increased manufacturing efficiencies. |
| 2027 |
USD 10–USD 30 |
Market matures with stable generic pricing; price declines slow. |
What factors could influence price changes?
- Regulatory interventions: Limits on price hikes for critical generic drugs.
- Market entry of biosimilars: Potential drug biosimilars could further reduce prices.
- Supply chain disruptions: Material shortages or manufacturing delays could temporarily increase prices.
- Insurance coverage and reimbursement policies: Impact affordability and thus market volume.
What is the outlook for market volume?
- The annual volume of injectable epinephrine in the U.S. exceeds 10 million units, reflecting broad emergency use.
- Export markets, especially Europe and Asia, are expanding, driven by increasing allergy awareness and regulatory approvals.
Key Takeaways
- The market for NDC 00003-0852 faces stable demand driven by emergency medical needs.
- Price trends show a gradual decline, with current prices around USD 20–USD 50 per unit for generics.
- Competition, regulatory policies, and supply stability will determine pricing dynamics over the next five years.
- The potential entry of biosimilar or alternative formulations could further push prices downward.
- Market volume remains robust, supported by increasing allergy prevalence and emergency preparedness initiatives.
FAQs
Q1: How does the price of generic epinephrine compare to branded versions?
A: Generic versions typically cost 40-60% less than brand-name auto-injectors like EpiPen.
Q2: Will the price of NDC 00003-0852 increase due to regulatory changes?
A: Unlikely. Regulatory pressures tend to stabilize or reduce prices for essential medicines.
Q3: Are there new formulations expected to impact this market?
A: Yes, alternative devices or formulations could enter the market, affecting pricing and volume.
Q4: How do supply chain issues influence this market?
A: Disruptions could cause temporary price spikes; however, long-term trends favor stabilization and price declines.
Q5: What are the key factors driving demand growth?
A: Rising allergy incidence, emergency preparedness policies, and wider availability in public and institutional settings.
References
- Grand View Research. Epinephrine Market Size, Share & Trends Analysis Report, 2023.
- IQVIA. U.S. Market Report for Injectable Epinephrine, 2022.
- U.S. Food and Drug Administration. Orange Book, 2023.
- Statista. Epinephrine Auto-Injectors Market Forecast, 2023–2030.
- Medicaid & Medicare Policy Reports. 2023.
